Advanced glycation end products in diabetes, cancer and phytochemical therapy. Issue 9 (September 2020)

• Record Type: Journal Article
• Authors: Dariya, Begum; Nagaraju, Ganji Purnachandra
• Is Part Of: Drug discovery today. Volume 25:Issue 9(2020)
• Page Start: 1614
• Page End: 1623
• Publication Date: 2020-09
• Subjects: Drugs -- Design -- Periodicals; Drugs -- Research -- Periodicals; 615.1
• DOI: 10.1016/j.drudis.2020.07.003
• Languages: English
• ISSNs: 1359-6446

Abstract

Highlights: Explores the mechanism of glycation and AGE production. Describes the aberrantly activated pathways through AGE-RAGE interaction. Emphasizes the important of glycation inhibition. Presents selected phytochemicals in inhibiting AGE production and cancer. Abstract : The irreversible glycation and oxidation of proteins and lipids produces advanced glycation end products (AGEs). These modified AGEs are triggered to bind the receptor for AGE (RAGE), thereby activating its downstream signaling pathways, such as nuclear factor (NF)-κB and phosphoinositide 3-kinase (PI3K)/Akt, ultimately leading to diabetes and cancers. In this review, we focus on the interaction of AGE–RAGE and their associated pathways. We also consider the activity of phytochemicals, such as genistein and curcumin, that trap dicarbonyl compounds including methylglyoxal (MG) and glyoxalase that arise from multiple pathways to block AGE formation and prevent its interaction with RAGE.